The expression and prognostic significance of Topo-II and c-erbB-2 in breast cancer.

BACKGROUND: This study aimed to investigate the expression and prognostic significance of topoisomeraseII (Topo-II）and c-erbB-2. METHODS: A total of 92 cases of patients with breast cancer who came to our hospital for treatment from November 2013 to January 2016 were included as the experimental group, and 90 healthy subjects who came to our hospital for physical examination during the same period were selected as the control group. ELISA was used to detect the expression levels of Topo-II and c-erbB-2 in serum of each group. The correlation among expression levels, degree of tumor differentiation and pathological types of Topo-II and c-erbB-2 in serum of patients with breast cancer were observed. RESULTS: The expression levels of Topo-II and c-erbB-2 in the experimental group were higher than those in the control group (P<0.05). The expression levels of Topo-II and c-erbB-2 in serum of patients with different stages increased with the clinical stages. The survival rate of patients with different expression levels of Topo-II and c-erbB-2 was compared, it was found that the survival rate of the low-expression group (80.49%) was significantly higher than that of the high-expression group (50.98%). The ROC curve was used to analyze Topo-II and c-erbB-2, the result showed that the sensitivity, specificity and AUC of Topo-II in the diagnosis of breast cancer was 72.22%, 94.56% and 0.8641, respectively. The sensitivity, specificity and AUC of c-erbB-2 in the diagnosis of breast cancer were 94.45%, 66.30% and 0.8379, respectively. CONCLUSIONS: In conclusion, Topo-II and c-erbB-2 are highly expressed in breast cancer and are closely related to breast cancer. Moreover, the detection of Topo-II and c-erbB-2 in serum can help diagnose gestational diabetes mellitus quickly and effectively.

Development of a novel insulin receptor (IR) antagonist that exhibits anti-breast tumor activity.

Many reports have indicated that the insulin receptor (IR) causes tumorigenesis and the development of breast cancer. It has been considered a potential target for treating IR-related tumors. Traditionally, there are two categories of insulin receptor (IR) antagonists, they are small molecule antagonists and anti-IR antibodies. Here, we describe a new method (anti-idiotypic antibody strategy) for the development of IR antagonist. Hybridoma technology was employed to design and identify a series of anti-idiotypic antibodies against insulin. After repeated screening and identification, an anti-idiotypic antibody against IR (AK98) was obtained. Analysis through competitive ELISA and competitive receptor binding indicated that AK98 mimicked the receptor binding epitope of insulin. The interaction between AK98 and IR was determined using indirect immunofluorescence, immunoelectron microscopy, and Immunoprecipitation-Western (IP-WB). Further research using a tumor cell model revealed that AK98 inhibited insulin-IR binding and IR-mediated intracellular signaling pathways. Conclusively, the main purpose of this paper is that we proposed a new method (anti-idiotypic antibody strategy) to develop the insulin receptor (IR) antagonist (AK98), and a series of experiments showed that the anti-idiotypic antibody (AK98) exhibited good antagonistic activity against IR. This work suggests that the anti-idiotypic antibody may be a potential strategy to develop IR antagonists that can be used in treating breast cancer.

The analysis of 15 cases with laparoscopic cholecystectomy-related unsuspected gallbladder cancer / 中国医师进修杂志

Objective To explore the diagnosis and treatment of unsuspected gallbladder cancer (UGC)related with laparoscopic cholecystectomy(LC).Methods From January 1995 to Dece m ber 2008,4520 cases of LC were performed,UGC waS discovered in 15 cases.Clinical data of the 15 cases were analyzed retrospectively.Results Among the 15 cases of UGC,7 were discovered intraoperatively,and 8 were diagnosed postoperatively.Postoperative pathological examination showed Nevin stage I in 4 cases,stage Ⅱin 7 cases,stage Ⅲ in 3 cases,stage Ⅳ in 1 case.LC was carried out in the patients of Nevin stage I.Radical resection of gallbladder cancer was performed on the patients at stage Ⅱ and stage Ⅲ.One patient at stage Ⅳ received extended radical resection.The patients were followed up from 6 months to 5 years,during the period 3 cases were died and 12 cases were still alive,the 5-year survival rate wag 80.0%.Conclusions Most of LC-related UGC cases are early cancer.Frozen section examination should be performed for high-risk groups and suspicious persons,which contributes to the discovery of UGC.LC can achieve the radical purpose of Nevin stage I patients,Nevin stage Ⅱ-Ⅳ requires open radical operation.